Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of molecular marker and its application for preparing biomarker reagent

A molecular marker and biomarker technology, applied in the fields of biotechnology, laboratory medicine, biochemistry and molecular biology, and clinical medicine, can solve the problems of many influencing factors and complex pathogenesis of neural tube defects, and achieve huge economic and The effect of social benefit

Active Publication Date: 2018-06-26
深圳臻合智造生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Purpose of the invention: the present invention is a molecular marker for prenatal non-invasive diagnosis of neural tube defects, and its application and use as a detection reagent. Specific markers to achieve accurate diagnosis and determination of the degree of disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of molecular marker and its application for preparing biomarker reagent
  • A kind of molecular marker and its application for preparing biomarker reagent
  • A kind of molecular marker and its application for preparing biomarker reagent

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] The application of the miRNA molecular marker of the present invention in the prenatal diagnosis of neural tube defects has achieved very satisfactory results. 33 pregnant women with neural tube defects and 33 normal pregnant women were selected, and the expressions of 6 miRNAs (miR-144, miR-142-3p, miR-720, miR-1275, miR-575 and miR-765) in the serum of these pregnant women were detected The results showed that miR-144, miR-142-3p, miR-720, miR-575 and miR-765 were significantly highly expressed in the serum of pregnant women with neural tube defects, and miR-1275 was significantly low expressed in the serum of pregnant women with neural tube defects. There were significant differences in comparison with the normal group. ROC curve analysis showed that the areas under the ROC curve (AUC) of miR-144, miR-720, miR-142-3p, miR-765, miR-1275 and miR-575 were 0.702, 0.680, 0.676, 0.646, 0.624 and 0.633. The area under the curve of the combined diagnosis of 6 miRNAs was 0.8...

Embodiment 2

[0043] The application of the ceruloplasmin of the present invention in the prenatal diagnosis of neural tube defects has also achieved very satisfactory results. The concentration of ceruloplasmin in the serum of 40 pregnant women with neural tube defects and 40 normal pregnant women was detected by ELISA method, and compared with the alpha-fetoprotein commonly used in clinical screening for neural tube defects. It has good sensitivity and specificity in diagnosis (the area under the ROC curve is 0.979), which is better than that of alpha-fetoprotein currently used clinically (the area under the ROC curve is 0.938) ( Figure 10 , Figure 11 shown).

Embodiment 3

[0045] The application of the proprotein convertase subtilisin 9 (PCSK9) of the present invention in the prenatal diagnosis of neural tube defects has also achieved very satisfactory results. Using ELISA method to detect the concentration of serum PCSK9 in 46 pregnant women with neural tube defects (Table 2) and 46 normal pregnant women, the results showed that the concentration of PCSK9 was higher in the 15-20 weeks of pregnancy, 23-27 weeks of pregnancy and 37-40 weeks of pregnancy. The serum levels of pregnant women were 215.80±88.41 ng / ml, 240.56±56.39 ng / ml, and 322.50±80.39 ng / ml, which were significantly lower than those of normal pregnant women (normal pregnant women at 15-20 weeks, 23-27 weeks and 37- 40 weeks were 297.00±61.51ng / ml, 333.23±66.40 ng / ml and 456.03±58.70 ng / ml) (P Figure 12 shown).

[0046] Table 2 Clinical data of pregnant women with neural tube defects

[0047]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a neural tube defect prenatal noninvasive diagnosis molecular marker which comprises 6 miRNA (miR-144, miR-142-3p, miR-720, miR-1275, miR-575 and miR-765) and 12 proteins (pro-protein convertase subtilisin / kexin 9, ceruloplasmin, leukaemia inhibitory factor, 14-3-3, paraoxonase, plasma alpha-globulin inhibiting factor H4, serum S protein, glycosyl-phosphatidylinositol specific phospholipase D1, fetuin A, amyloid protein P, plasma alpha-globulin inhibiting factor H2 and platelet factor 4). The invention further provides application of the molecular marker.

Description

technical field [0001] The invention belongs to the fields of laboratory medicine, clinical medicine, biotechnology, biochemistry and molecular biology, and specifically relates to a molecular marker for prenatal non-invasive diagnosis of neural tube defects, and its application and use method as a detection reagent. Background technique [0002] Neural tube defects (NTDs), including anencephaly, spina bifida, encephalocele, hydrocephalus, etc., are serious birth defects. There are 300,000 to 400,000 cases of neural tube defects in the world every year, and the incidence rate in China is significantly higher than that in Western countries. The pathological changes of neural tube defects are complex, resulting in poor treatment effect. In recent years, although the prevalence of folic acid supplementation during pregnancy has increased, the incidence of neural tube defects has decreased. However, since neural tube defects are complex polygenic diseases caused by the combine...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N21/76
CPCG01N21/76G01N2800/28
Inventor 袁正伟顾卉安东李慧魏晓伟刘丹
Owner 深圳臻合智造生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com